Update on COVID-19 research at Helix

Data from Helix's research community is helping scientists around the world, including a recent finding published in the New England Journal of Medicine.

Read more...

Beyond the cough: symptoms and trends from a COVID-19 survey

Our team of researchers are currently working through the data, but we have already found some interesting insights in our collection of survey responses, and we’ve contributed our findings to a worldwide research effort, consisting...

Read more...

Saliva-based COVID-19 testing is less sensitive than nasopharyngeal swabs in the community setting

Helix researchers, along with collaborators from Renown Health and UC San Diego, found that, relative to nasopharyngeal swabs, the sensitivity of saliva was approximately 30% lower in a community-based diagnostic cohort and 50% lower...

Read more...

Exploring the influence of genetics on COVID-19

Helix researchers to leverage user input and exome-sequencing data to understand COVID-19 risk and severity The spread of the novel SARS-CoV-2 coronavirus has led to the unfolding COVID-19 pandemic. In addition to demonstrating a high...

Read more...

Revealing variants in SARS-CoV-2 interaction domain of ACE2 and loss of function intolerance through analysis of >200,000 exomes

Our analysis suggests that variants in the ACE2 gene--particularly those in the regions that interact with the SARs-COV-2 virus--have the potential to show important associations with COVID-19 susceptibility and resistance.

Read more...

Helping your engineers grow

As a manager, it can be unclear where someone’s career was before they met you and how they view their long term ambitions. And when the work is getting done now, it is easy to...

Read more...

DNA testing for prostate cancer risk: Here’s what you need to know

Prostate cancer is a condition many of us have heard of, but rarely do we think about it potentially affecting us. We probably should, though, because approximately one out of every seven males will develop...

Read more...